Quick Answer
XTL BIOPHARMACEUTICALS LTD reported Research And Development Expense of $98.0 thousand for the year ending 2024.
- XTL BIOPHARMACEUTICALS LTD showed an increase of +216.1% in Research And Development Expense from 2023 to 2024.
- This data is from XTL BIOPHARMACEUTICALS LTD's annual report (Form 10-K), filed with the SEC on April 30, 2025.
- XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2015 to 2024), XTL BIOPHARMACEUTICALS LTD's Research And Development Expense has declined by 83.0%.
- Historical annual values: Fiscal year 2024: $98.0 thousand | Fiscal year 2023: $31.0 thousand | Fiscal year 2022: $30.0 thousand | Fiscal year 2021: $30.0 thousand | Fiscal year 2020: $38.0 thousand | Fiscal year 2019: $35.0 thousand | Fiscal year 2018: $38.0 thousand | Fiscal year 2017: $43.0 thousand | Fiscal year 2016: $443.0 thousand | Fiscal year 2015: $578.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: